【摘要】 目的 探讨表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKIs)一线治疗根治术后复发的EGFR基因突变型非小细胞肺癌(NSCLC)患者的有效性和安全性。方法 62例NSCLC根治术后复发患者接受EGFR-TKIs一线治疗，患者均携带EGFR基因突变。回顾性分析EGFR-TKIs一线治疗的疗效、不良反应以及患者无进展生存期(PFS)和3年总生存率。结果 EGFR-TKIs一线治疗的客观缓解率和疾病控制率分别为51.6%和91.9%。2例(3.2%)患者出现3级及以上不良反应，其中1例为中性粒细胞减少，1例为手足综合征。随访4～36个月，自开始EGFR-TKIs治疗的中位PFS为10.3个月。一、二代和三代EGFR-TKIs治疗的中位PFS分别为8.0个月和16.5个月，3年总生存率分别为6.5%和22.5%。Kaplan-Meier生存曲线分析结果显示奥希替尼能延长患者的PFS(P=0.004)。结论 EGFR-TKIs一线治疗根治术后复发的EGFR基因突变型NSCLC是一个合理的选择。奥希替尼具有延长PFS的趋势。更多还原

【Abstract】 Objective To investigate the efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs) in the first-line treatment of the patients with recurrent EGFR gene mutant-type non-small cell lung cancer(NSCLC) after radical resection.Methods Sixty-two patients with recurrent EGFR gene mutant-type NSCLC after radical resection received EGFR-TKIs first-line treatment.The efficacy, adverse response, progression free survival(PFS) and 3-year overall survival(OS) rate of EGFR-TKIs were retrospectively analyzed.ResultsThe objective response rate and disease control rate were 51.6% and 91.9%,respectively.Two patients(3.2%) had grade 3 or higher adverse responses, including 1 case of neutropenia and 1 case of hand-foot syndrome.Followed-up for 4 to 36 months, the median PFS was 10.3 months from the beginning of EGFR-TKIs therapy.The median PFS of the first/second-and third-generation EGFR-TKIs was 8.0 months and 16.5 months, and the 3-year OS rate was 6.5% and 22.5%,respectively.Kaplan-Meier analysis showed that osimertinib could prolong the PFS of the patients(P=0.004).Conclusion EGFR-TKIs are the reasonable choices for the first-line treatment of recurrent EGFR gene mutant-type NSCLC after radical resection.Osimertinib has a tendency to prolong PFS of the patients.更多还原